688075 安旭生物
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入71,199-38.25%451,255540,698503,3576,165,884
减:营业总成本120,853-0.72%531,111502,119442,7091,967,504
    其中:营业成本42,150-36.62%259,452329,275290,4451,554,904
               财务费用38,5151,698.98%57,497(38,377)(70,937)(533,589)
               资产减值损失----(8,122)(12,778)(23,966)(763,897)
公允价值变动收益7,842-30.70%26,57363,427(54,802)(9,421)
投资收益23,299-16.96%128,209118,212140,10758,418
    其中:对联营企业和合营企业的投资收益------------
营业利润(14,167)-140.68%69,572207,583167,4843,528,837
利润总额(14,143)-140.59%74,873210,640143,8173,519,508
减:所得税费用(3,788)-718.48%5,66318,4032,852475,336
净利润(10,354)-130.25%69,210192,237140,9653,044,172
减:非控股权益6-97.06%(212)(58)(589)(502)
股东净利润(10,360)-130.44%69,421192,295141,5543,044,673

市场价值指针
每股收益 (元) *-0.080-129.63%0.5501.5101.11023.950
每股派息 (元) *----0.8001.2000.4005.000
每股净资产 (元) *40.529-1.63%40.64040.94740.20659.730
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容